🏛️ Verified NIH Record • Updated 2025-12-16
Zemaira Eosinophilic Esophagitis Pilot Study (NCT05485155)
An Open-Label Study of Zemaira (Alpha 1-Trypsin Inhibitor) in Subjects With Eosinophilic Esophagitis
🟢 Recruiting Phase2 💊 Investigational Drug / Biologic Sponsor: Children's Hospital Medical Center, Cincinnati
🩺 Plain-English Summary (8th-Grade Level)
This is a prospective, open-label drug study that will examine the effects of Zemaira (alpha-1 trypsin inhibitor) in patients with Eosinophilic Esophagitis.
Who can join: Review the eligibility criteria below.
Location: The National Institutes of Health — Bethesda, Maryland
Age range: 18 Years to 70 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (2 Sites)
- The National Institutes of Health — Bethesda, Maryland
- Cincinnati Children's Hospital Medical Center — Cincinnati, Ohio
📞 Contact the Study Coordinator
Phone: (513) 517-2108
Email: Regina.Yearout@cchmc.org
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Eosinophilic Esophagitis
- Efficacy and Safety of Tezepelumab in Patients With Eosinophilic Esophagitis — Phoenix, Arizona
- Efficacy of Low-Dose Topical Steroids in Maintaining Remission of Eosinophilic Esophagitis in Children — Chicago, Illinois
- A Prospective Study of the Four Food Elimination Diet for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
- Dupilumab for Eosinophilic Esophagitis With Severe Strictures — Chapel Hill, North Carolina
- Cow's Milk Elimination for Treatment of Eosinophilic Esophagitis — Chicago, Illinois
- A Study in Adult Participants With EoE to Evaluate Vonoprazan 20 mg Compared to Placebo After 12 Weeks and to Evaluate Vonoprazan 20 mg Up to 24 Weeks — Little Rock, Arkansas
Explore by condition: All Eosinophilic Esophagitis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.